- Home
- NUVL vs EQX Comparison
NUVL vs EQX Comparison
Compare NUVL & EQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVL | EQX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 10.9B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NUVL | EQX |
|---|---|---|
| Price | $109.56 | $13.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $134.29 | $17.00 |
| AVG Volume (30 Days) | 756.3K | ★ 8.3M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $2,296,356,000.00 |
| Revenue This Year | N/A | $78.78 |
| Revenue Next Year | N/A | $60.10 |
| P/E Ratio | ★ N/A | $175.53 |
| Revenue Growth | N/A | ★ 85.65 |
| 52 Week Low | $55.54 | $4.95 |
| 52 Week High | $112.88 | $14.36 |
Technical Indicators
Market Signals| Indicator | NUVL | EQX |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 66.28 |
| Support Level | $103.51 | $13.62 |
| Resistance Level | $112.11 | $14.27 |
| Average True Range (ATR) | 5.16 | 0.56 |
| MACD | -0.24 | 0.08 |
| Stochastic Oscillator | 83.81 | 84.30 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.